Growth Metrics

Lemaitre Vascular (LMAT) Cost of Revenue (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Cost of Revenue for 16 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue fell 47.6% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.8 million through Dec 2025, down 9.81% year-over-year, with the annual reading at $71.1 million for FY2025, 3.05% up from the prior year.
  • Cost of Revenue for Q4 2025 was $18.3 million at Lemaitre Vascular, up from $15.1 million in the prior quarter.
  • The five-year high for Cost of Revenue was $34.9 million in Q4 2024, with the low at -$11.8 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $13.2 million, with a median of $14.1 million recorded in 2022.
  • The sharpest move saw Cost of Revenue tumbled 130.1% in 2023, then surged 456.97% in 2024.
  • Over 5 years, Cost of Revenue stood at -$11.8 million in 2021, then soared by 373.94% to $32.4 million in 2022, then crashed by 130.1% to -$9.8 million in 2023, then soared by 456.97% to $34.9 million in 2024, then tumbled by 47.6% to $18.3 million in 2025.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $18.3 million, $15.1 million, and $19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.